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Abstract 
A facile and general synthetic methodology has been developed to prepare high drug loading 
heterotelechelic polymer prodrug nanoparticles; that are nanoparticles obtained by formulation of 
linear polymers bearing two different molecules at both extremities (at least one of them being a 
drug). The method relied on the combination of the “drug-initiated” method to obtain α-functional 
polymer prodrugs by nitroxide-mediated polymerization, followed by the nitroxide exchange reaction 
from a functional nitroxide to install another molecule of interest at the ω chain-end. To validate the 
proof of concept, two different combinations have been synthesized using polyisoprene (PI) as the 
polymer building block: one based on gemcitabine and rhodamine (Gem-PI-Rho) for drug delivery 
and imaging purposes, and one with aminoglutethimide and doxorubicin (Agm-PI-Dox) for 
combination therapy purposes. Fluorescent polymer prodrug nanoparticles (Dz = 161 nm) were easily 
obtained by co-nanoprecipitation of Gem-PI and 5 wt.% of Gem-PI-Rho. They were observed by 
confocal microscopy and they also induced significant cytotoxicity on the human breast cancer cell 
line MCF7. As for combination therapy purposes, Agm-PI-Dox nanoparticles (Dz = 63-122 nm) led 
to enhanced cytotoxicity against MCF7 cells compared to both monofunctional polymer prodrug 
nanoparticles (ca. 50% decrease in IC50 vs. Agm-PI and 65% decrease in IC50 vs. PI-Dox) or their 
equimolar co-nanoprecipitation. This simple and general methodology may pave the way to the 
design of a broad range of different heterotelechelic polymer prodrug nanoparticles. 
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1. Introduction 
Polymer prodrug nanocarriers are receiving increasing attention as a promising strategy to circumvent 
the main limitations associated with the traditional encapsulation of drugs into nanoparticulate 
systems [1, 2]. A chemical linkage between the drug and the polymer scaffold indeed comes with 
important advantages compared to a simple physical encapsulation, such as: (i) avoiding the “burst 
release” (i.e., the sudden and quick release of a significant amount of drug after administration); (ii) 
reaching higher drug loadings and (iii) allowing the delivery of drugs that are hardly compatible with 
the polymer matrix/core. 
Polymer prodrug nanocarriers are typically synthesized following three different routes: (i) 
the “grafting to” strategy, which relies on a drug coupling on a preformed polymer; (ii) the “grafting 
through” strategy, consisting in the polymerization of a monomer-bearing drug and (iii) the “drug-
initiated” approach [3], for which the polymer is grown in a controlled fashion from a drug 
functionalized by an initiating moiety. The latter method offers significant benefits compared to the 
two other ones, such as its simplicity (e.g., a few synthetic steps, simpler purification workup, etc.), 
a quantitative functionalization of the polymer by the drug, adjustable drug loadings (up to ~40 wt.%) 
by fine tuning the polymer chain length and the possibility to be virtually applied to any kind of drug 
and polymer. 
Over the past few years, the versatility and robustness of the “drug-initiated” approach was 
successfully illustrated by its application to many drug/polymer pairs from different polymerization 
techniques. For instance, ionic ring-opening polymerization (ROP) [4-12] was used to prepare 
hydrophobic polyester prodrugs nanoparticles based on taxane derivatives, with high drug loadings 
but that required post-stabilization by PEG-based surfactants to ensure the colloidal stability. Polymer 
chains were also grown from gemcitabine (Gem), cladribine and paclitaxel by reversible-deactivation 
radical polymerization (RDRP) techniques; in particular nitroxide-mediated polymerization (NMP) 
[13-16] and reversible addition-fragmentation chain transfer (RAFT) [15, 17-21] polymerization. 
These radical polymerization techniques possess great advantages compared to ionic ROP such as 
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mild reaction conditions, great versatility of the polymer structure and composition, the possibility to 
design well-defined, complex architectures as well as the ease and diversity of polymer 
functionalization. Interestingly, polymer prodrugs made by RDRP led to surfactant-free nanoparticles 
with high colloidal stability, drug loadings up to 30 wt.% and significant cytotoxicity both in vitro 
and in vivo.  
In the biomedical field, heterotelechelic polymers (i.e., end-functional polymers bearing 
different reactive end-groups at both chain-ends) are particularly interesting as they offer an 
opportunity to embed two different biologically active entities at both chain-ends, such as drugs, 
ligands or imaging agents [22]. However, synthetic strategies to achieve such constructs are generally 
laborious and not versatile. Also, no example of heterotelechelic polymers bearing two different drugs 
at the chain ends for combination therapy has ever been reported, which still represents an unmet 
synthetic challenge. Combination therapy, that relies on the simultaneous administration of two or 
more drugs, is increasingly used to treat various diseases, including HIV [23, 24], malaria [25, 26] 
and cancer [27, 28]. Compared to monotherapy, it can overcome some resistance mechanisms, 
modulate different signaling pathways, maximize the therapeutic effect and even induce a synergy, 
and reduce adverse effects, which altogether generally lead to better long term prognosis [29, 30]. 
The development of a facile synthetic route to heterotelechelic polymer prodrug nanoparticles that 
could be used for drug delivery, imaging or combination therapy purposes would therefore provide 
the community with new synthetic and therapeutic opportunities. 
In this context, we propose a robust and general, yet simple methodology to design highly 
versatile heterotelechelic polymers for drug delivery applications. The idea is to take advantage of 
the “drug-initiated” method performed by NMP and the high chain-end retention of the controlling 
agent that offers a robust and flexible post-functionalization opportunity at the ω-chain-end via 
nitroxide exchange reaction from functional nitroxides (Figure 1). The efficiency of our approach 
was illustrated by the design of two very different combinations to validate the proof of concept; one 
for drug delivery and imaging (i.e., one drug and one imaging probe) and one for combination therapy 
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(i.e., two different drugs). The different heterotelechelic polymer prodrugs will be formulated into 
the corresponding prodrug nanoparticles and evaluated for their imaging properties by confocal 
microscopy and cytotoxicity on human breast cancer cells. 
 
 
Figure 1. Synthetic strategy to well-defined, heterotelechelic polymer prodrug nanoparticles for 
imaging, drug delivery and combination therapy by combining the “drug-initiated” method applied 
to nitroxide-mediated polymerization (NMP) and the nitroxide exchange reaction from a functional 
nitroxide.  
 
2. Materials and Methods 
2.1 Materials 
Gemcitabine (Gem, > 98%), aminoglutethimide (Agm) and doxorubicin·HCl (Dox) were purchased 
from Carbosynth Limited (UK). Benzotriazol-1-yloxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP), N,N-diisopropylethylamine (DIPEA), isoprene, 4-
(dimethylamino)pyridine (DMAP), succinic anhydride, 4-hydroxy-TEMPO, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU), rhodamine B base (Rho) were purchased from Sigma-Aldrich (France) and used as 
received. AMA-SG1 [31] and Gem-AMA-SG1 [13] alkoxyamines as well as Rho-piperazine [32]  
were prepared as reported previously. All other reactants were purchased from Sigma-Aldrich at the 
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highest available purity and used as received. Deuterated chloroform (CDCl3) was obtained from 
Eurisotop. All other solvents were purchased from Carlo-Erba at the highest grade. Eagle's Minimum 
Essential Medium (EMEM) and fetal bovine serum (FBS) were purchased from Dulbecco 
(Invitrogen, France). Penicillin and streptomycin were obtained from Lonza (Verviers, Belgium). 
LysoTracker Green and Hoechst 33342 were purchased from Life Technologies. N-tert-butyl-N-(1-
diethylphosphono-2,2-dimethylpropyl) nitroxide (SG1, 85%) was kindly supplied by Arkema. 
 
2.2 Analytical methods 
Nuclear Magnetic Resonance Spectroscopy (NMR). NMR spectroscopy was performed in 5 mm 
diameter tubes in CDCl3 at 25 °C. 1H and 13C NMR spectroscopy was performed on a Bruker Avance 
300 spectrometer at 300 MHz (1H) or 75 MHz (13C). The chemical shift scale was calibrated based 
on the internal solvent signals. To characterize nitroxide derivatives, pentafluorophenylhydrazine was 
added in situ and allowed to react before the analysis [33, 34]. 
Mass spectrometry. Mass spectra were recorded with a Bruker Esquire-LC instrument. High-
resolution mass spectra (ESI) were recorded on an ESI/TOF (LCT, Waters) LC-spectrometer.  
Size Exclusion Chromatography (SEC). SEC was performed at 30 °C with two columns from 
Polymer Laboratories (PL-gel MIXED-D; 300 × 7.5 mm; bead diameter 5 mm; linear part 400 to 4 × 
105 g.mol-1), a differential refractive index detector (Spectra System RI-150 from Thermo Electron 
Corp.) and a scanning fluorescence detector (Waters 474). The eluent was chloroform at a flow rate 
of 1 mL.min-1 (Waters 515 pump) and toluene was used as a flow-rate marker. The calibration curve 
was based on polystyrene (PS) standards (peak molar masses, Mp = 162–523 000 g.mol-1) from 
Polymer Laboratories. A polyisoprene (PI) calibration curve was constructed by converting the PS 
standard peak molecular weights (MPS) to PI molecular weights (MPI) using Mark-Houwink-Sakurada 
(MHS) constants determined for both polymers in CCl4 at 25 °C. For PI, the MHS constants used 
were KPI = 2.44 × 104 and αPI = 0.712. For PS, KPS = 7.1 × 104 and αPS = 0.54 (Mw < 16 700 g.mol-1) 
or KPS = 1.44 × 104 and αPS = 0.713 (Mw > 16 700 g.mol-1) [13]. This technique allowed Mn (the 
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number-average molar mass), Mw (the weight-average molar mass), and Mw/Mn (the dispersity, Ð) to 
be determined. 
Dynamic Light Scattering (DLS) and zeta potential. Nanoparticle diameters (Dz) and zeta 
potentials (ζ) were measured by dynamic light scattering (DLS) with a Nano ZS from Malvern (173° 
scattering angle) at a temperature of 25 °C. The surface charge of the nanoparticles was investigated 
by ζ-potential (mV) measurement at 25 °C after dilution with 1 mM NaCl, using the Smoluchowski 
equation. 
Cryogenic Transmission Electron Microscopy (cryo-TEM). The morphology of the nanoparticles 
was observed by cryo-TEM. Briefly, 5 μL of the nanoparticle suspension (0.5 mg.mL-1) was deposited 
on a Lacey Formvar/carbon 300 mesh copper microscopy grid (Ted Pella). Most of the drop was 
removed with a blotting filter paper and the residual thin film remaining within the holes was vitrified 
by plunging into liquid ethane. Samples were then observed using a JEOL 2100HC microscope. 
Electronic Spin Resonance (ESR). Determination of the dissociation rate constant (kd). ESR 
experiments were performed on a Bruker EMX 300 spectrometer. The appearance of the nitroxide 
was followed during the thermolysis of the PI macroalkoxyamine ([PI]0 = 1.0 ×10-4 M) in tert-
butylbenzene as solvent (0.6 mL). O2 was used as radical scavenger. The time evolution of the doubly 
integrated ESR signal of the TEMPO and SG1 nitroxide radical was followed by ESR spectroscopy 
at 413 and 385.5 K for 4 h. A first-order fit of the signal allowed the determination of the kd value. 
The activation energy Ea was calculated from kd via the Arrhenius equation with A = 2.4 × 1014 s-1 as 
described elsewhere [32].  
Determination of the living fraction (LF) of PI-SG1. A PI-SG1 solution ([PI]0 = 1.0 × 10-4 M) in tert-
butylbenzene (0.6 mL) was prepared. The residual amount of nitroxide was first determined by ESR 
using TEMPO solutions as external standards. The solution was then heated up at 393 K for 2 h in 
open air since O2 was used as radical scavenger. The solution was then analyzed by ESR and the 
concentration of the released nitroxide determined using TEMPO solutions as external standards. The 
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living fraction of the polymer chain was then obtained by the difference between the nitroxide 
concentration after and before thermolysis. 
Monitoring of the exchange by in situ ESR. A 10-3 M pyridine solution of the TEMPO-Rho nitroxide 
and a Gem-PI-SG1 macroalkoxyamine (1:1 eq) was prepared and inserted into a 3 mm-ESR tube. 
The tube was degassed for 15 min by argon bubbling. The tube was then inserted into a Bruker EMX 
300 spectrometer equipped with a Temperature Control System. The temperature was set to 383 K 
and the signal was monitored every minute for 16 h. 
 
2.3 Synthesis 
Synthesis of Agm-AMA-SG1. Aminoglutethimide (Agm, 0.5 g, 2.15 mmol) was dissolved in 5 mL 
of dry DMF. PyBOP (1.12 g, 2.15 mmol) and AMA-SG1 (0.790 g, 2.15 mmol) were dissolved in 5 
mL of dry DMF in another round-bottomed flask, stirred for 15 minutes and added by syringe to the 
first solution. DIPEA (1.11 g, 8.6 mmol) was added dropwise by syringe. The solution was stirred 
under argon atmosphere for 24 h at room temperature, then diluted with 100 mL EtOAc.The organic 
phase was washed with 1 M HCl, sat. NaHCO3 aqueous solution, and brine before being dried over 
MgSO4. The residue was concentrated under reduced pressure and purified by flash chromatography 
(SiO2, gradient from Cyclohexane/EtOAc1/1 v/v to EtOAc as eluent) to give 0.86 g of Agm-AMA-
SG1 as a white solid. Yield: 69%. 1H NMR (CDCl3, 300 MHz): δ 10.08 (s, 1H, Ha), 8.34 (s, 1H, Hb), 
7.80 (d, 2H, Hc), 7.22 (d, 2H, Hc), 4.61 (q, 1H, Hd), 4.11 (m, 4H, He), 3.33 (d, 1H, Hf), 2.61-1.90 (m, 
6H, Hg), 1.72 (d, 3H, Hh), 1.19 (m, 24H, Hi), 0.86 (t, 3H, Hl). 13C NMR (75 MHz, CDCl3) δ 175.13, 
172.26, 171.90, 138.19, 133.49, 126.53, 120.64, 81.85, 69.73, 67.91, 62.50, 61.95, 61.86, 60.28, 
60.18, 50.74, 35.61, 32.84, 29.96, 29.32, 28.39, 27.10, 18.95, 16.47, 16.16, 9.02.MS (ESI+): m/z = 
604.3 (M+Na)+. Calc. for C29H48N3O7P: 581.32. 
Synthesis of Agm-PI-SG1. Agm-AMA-SG1 (200 mg, 0.344 mmol) was placed in a 15 mL-capacity 
pressure tube (Ace Glass 8648-164) fitted with plunger valves and thermowells. After addition of 
isoprene (5.15 mL, 51.6 mmol) and dioxane (5.15 mL), the tube underwent three cycles of freeze-
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thaw degassing and was then backfilled with argon. The tube was then placed in a preheated oil bath 
at 115 °C for 4 (A1) or 16 h (A2) and then cooled down to room temperature by placing it under cold 
water. The residue was concentrated under reduced pressure and precipitated in cold methanol to give 
Agm-PI-SG1 as a colorless viscous oil. Another polymerization was performed for 16 h with 
[isoprene]0/[Agm-AMA-SG1]0 = 300/1 (A3). All polymers were characterized by SEC and 1H NMR. 
Synthesis of Gem-PI-SG1. A procedure previously published by our group was followed [13]. 
Briefly, Gem-AMA-SG1 (200 mg, 0.326 mmol) was placed in a 15 mL-capacity pressure tube (Ace 
Glass 8648-164) fitted with plunger valves and thermowells. After addition of isoprene (6.5 mL, 65.3 
mmol) and dioxane (6.5 mL), the tube underwent three cycles of freeze-thaw degassing and was then 
backfilled with argon. The tube was placed in a preheated oil bath at 115 °C for 8 h (G2) or 16 h (G4, 
G5) and then cooled to room temperature by placing it under cold water. The residue was 
concentrated under reduced pressure and precipitated in cold methanol to give Gem-PI-SG1 as a 
colorless viscous oil. Other polymerizations were performed for 16 h with [isoprene]0/[Gem-AMA-
SG1]0 = 100/1 (G1, G3) or [isoprene]0/[Gem-AMA-SG1]0 = 400/1 (G6). All polymers were 
characterized by SEC and 1H NMR. 
Synthesis of PI-SG1. AMA-SG1 (100 mg, 0.27 mmol) was placed in a 15 mL-capacity pressure tube 
(Ace Glass 8648-164) fitted with a plunger valve and thermowell. After addition of isoprene (5.4 mL, 
5.4 mmol) and dioxane (5.4 mL), the tube underwent three cycles of freeze-thaw degassing and was 
then backfilled with argon. The tube was placed in a preheated oil bath at 115 °C for 16 h (P1) and 
then cooled to room temperature by placing it under cold water. The residue was concentrated under 
reduced pressure and precipitated in cold methanol to give PI-SG1 as a colorless viscous oil. Mn,SEC 
= 2140 g.mol-1, Ð = 1.17. 
Synthesis of succynic-TEMPO (4-(1-oxyl-2,2,6,6-tetramethylpiperidin-4-yloxy)-4-oxobutanoic 
acid). Succynic-TEMPO was prepared according to published procedure [35]. Briefly, a solution of 
DMAP (6.38 g, 52.3 mmol) and succinic anhydride (5.23 g, 52.3 mmol) in DCM (30 mL) was added 
dropwise, at 0 °C and under an argon atmosphere, to a solution of 4-hydroxyTEMPO (3.00 g, 17.4 
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mmol) in DCM (20 mL). After stirring overnight at room temperature, the solution was quenched 
with 1 M HCl. The product was extracted three times with DCM. The combined organic layers were 
washed with brine, dried over MgSO4. After evaporation of the solvent, succynic-TEMPO was 
obtained as a white solid. Yield: 98%. 1H NMR (CDCl3, 300 MHz): δ 4.97 (m, 1H), 2.63 (t, 2H), 2.47 
(t, 2H), 2.27 (d, 2H), 1.93 (t, 2H), 1.39 (s, 6H), 1.29 (s, 6H). 
Synthesis of TEMPO-Rho. DIPEA (1.33 mL, 2 eq) was added by syringe to a solution of HATU 
(2.2 g, 1.5 eq) and succinic-TEMPO (1.1 g, 1 eq) in DMF (10 mL). After 30 min of stirring, the 
mixture was added to a solution of Rho-piperazine (2.0 g, 1 eq) and DIPEA (0.66 mL, 1 eq) in DMF 
(5 mL) and the reaction was stirred at room temperature for 3 h. The mixture was then washed with 
saturated NaHCO3. The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pression. After purification by flash chromatography (SiO2, DCM/MeOH 
99/1 v/v as eluent), 2.0 g of TEMPO-Rho were obtained, as a purple solid. Yield: 68%. 1H NMR 
(CDCl3, 300 MHz): δ 7.69-6.71 (m, 10H), 5.05 (m, 1H), 3.62 (m, 8H), 3.46 (m, 8H), 2.58 (m, 4H), 
1.94 (m, 2H), 1.65 (m, 2H), 1.33 (t, 12H), 1.21 (m, 12H). MS (ESI+): m/z = 765.8 (M)+. Calc. for 
C45H59N5O6: 765.45. 
Synthesis of TEMPO-Dox. DIPEA (0.64 mL, 2 eq) was added by syringe to a solution of HATU 
(0.84 g, 1.2 eq) and succinic-TEMPO (0.50 g, 1 eq) in DMF (7 mL). After 30 min of stirring, the 
mixture was added to a solution of doxorubicin (1.0 g, 1 eq) and DIPEA (0.32 mL, 1 eq) in DMF (3 
mL) and the reaction was stirred at room temperature for 3 h. Water was added and then extracted 
three times with DCM. The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pression. After purification by flash chromatography (SiO2, DCM/MeOH 
98/2 v/v as eluent), 0.63 g of TEMPO-Dox were obtained, as a red-orange solid. Yield: 45%. 1H NMR 
(CDCl3, 300 MHz): δ 8.06 (d, 1H), 7.80 (t, 1H), 7.41 (d, 1H), 6.11 (m, 1H), 5.52 (s, 1H), 5.30 (s, 1H), 
5.06 (m, 1H), 4.77 (s, 2H), 4.66 (m, 1H), 4.09 (s, 3H), 3.68 (s, 1H), 3.07-2.90 (m, 2H), 2.75-1.59 (m, 
12H), 1.35-1.18 (m, 15H). MS (ESI-): m/z = 796.3 (M)-. Calc. for C40H49N2O15: 797.31. 
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Synthesis of Gem-PI-Rho (G2R and G3R). Briefly, 300 mg of Gem-PI (1 eq) and TEMPO-Rho (1 
eq) were placed in a 7 mL-vial and dissolved in 1 mL of dry pyridine. After 20 min of degassing 
under argon, the vial was placed in a preheated oil bath at 110 °C and stirred for 16 h. Gem-PI-Rho 
was then precipitated two times in cold methanol and dried under reduced pressure until constant 
weight. The post-functionalization yield was calculated by 1H NMR using the chemical shifts of 
aromatic protons of Rho (δ = 7.70, 7.55, 7.08 and 6.93-6.67 ppm) and the chemical shifts of aromatic 
protons and anomeric proton of Gem (δ = 8.26, 7.48 and 6.26 ppm). Functionalization was confirmed 
by SEC equipped with a fluorescent detector (λex = 570 nm, λem = 595 nm). 
Synthesis of Agm-PI-Dox (A1D-A3D). Briefly, 300 mg of Agm-PI (1 eq) and TEMPO-Dox (1 eq) 
were placed in a 7 mL-vial and dissolved in 1 mL of dry pyridine. After 20 min of degassing under 
argon, the vial was placed in a preheated oil bath at 110 °C and stirred for 16 h. Agm-PI-Dox was 
then precipitated two times in cold methanol and dried under reduced pressure until constant weight. 
The post-functionalization yield was calculated by 1H NMR using the chemical shifts of aromatic 
protons of Dox (δ = 8.15, 7.79 and 7.37 ppm) and the chemical shifts of aromatic proton of Agm (δ 
= 7.53 and 7.23 ppm). The amount of Dox was also determined by UV spectrophotometry at 480 nm 
(Perkin-Elmer UV/vis spectrophotometer, Germany). Functionalization was confirmed by SEC 
equipped with a fluorescent detector (λex = 480 nm, λem = 570 nm). 
Synthesis of PI-Dox (D1). Briefly, 300 mg of PI-SG1 (P1, 1 eq) and TEMPO-Dox (1 eq) were placed 
in a 7 mL-vial and dissolved in 1 mL of dry pyridine. After 20 min of degassing under argon, the vial 
was placed in a preheated oil bath at 110 °C and stirred for 16 h. PI-Dox was then precipitated two 
times in cold methanol and dried under reduced pressure until constant weight. Mn,SEC = 3210 g.mol-
1, Ð = 1.22. The amount of doxorubicin was also determined by UV spectrophotometry at 480 nm 
(Perkin-Elmer UV/vis spectrophotometer, Germany) and was 65%. Functionalization was confirmed 
by SEC equipped with a fluorescent detector (λex = 480 nm, λem = 570 nm). 
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2.4 Nanoparticle preparation  
Nanoparticles P1, G4, A3, A1D-A3D and A3coD1 (1:1, mol:mol) were prepared by the 
nanoprecipitation technique [36]. Briefly, 2.5 mg of the corresponding polymer was dissolved in 0.5 
mL of THF and quickly added to 1 mL MilliQ water. THF was evaporated at ambient temperature 
using a Rotavapor. Intensity-average diameter (Dz) and zeta potential measurements were carried out 
in triplicate by DLS. Their colloidal stability was assessed in water for 30 days and in cell culture 
medium supplemented with 10% serum for 13 days. The nanoparticles were kept at 4°C and allowed 
to reach room temperature before every measurements.  
Gem-PI (G4) was also blended and co-nanoprecipitated with 5 wt.% of Gem-PI-Rho (G3R). 
Briefly, 0.95 mg of G4 and 0.05 mg of G3R were dissolved in 0.5 mL of THF and quickly added to 
1 mL MilliQ water. THF was evaporated at ambient temperature using a Rotavapor. Intensity-average 
diameter (Dz) and zeta potential measurements were carried out in triplicate by DLS.  
 
2.5 Cell lines and cell culture 
MCF-7 human breast cancer cell line was obtained from the American Type Culture Collection 
(ATCC) and maintained as recommended. Briefly, MCF-7 cells were grown in Eagle's Minimum 
Essential Medium (EMEM). All media were supplemented with 10% heat-inactivated FBS (56 °C, 
30 min), penicillin (100 U mL-1) and streptomycin (100 μg.mL-1), 1% non-essential amino acids 
(NEAA) and 5 mL glutamine. Cells were maintained in a humid atmosphere at 37 °C with 5% CO2. 
 
2.6 Confocal microscopy 
MCF-7 cells (2 × 105 per well) were cultured on a coverslip in a culture dish for 24 h to achieve ~60% 
confluence. Cells were then incubated at 37 °C with free Dox or A3D at the concentration of 10 μM 
for 90 min, or G4coG3R at the concentration of 5 μM for 90 min. After treatment, the cells were 
washed with PBS, stained with LysoTracker Green for 30 min, washed again with PBS and stained 
with Hoechst 33342 for 20 min under the same incubation conditions. The cells were then washed 
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two times with PBS, before addition of medium and imaged by Confocal Laser Scanning Microscopy 
(CLSM, Leica TCS SP8) with a HC PL APO CS2 (63x/1.40 Oil) oil-immersion objective. The 
fluorescence was collected in the range of 412–466 m (λex = 405 nm, Hoechst 33342), 508–531 nm 
(λex = 504 nm, Lysotracker Green), 558–708 nm (λex = 552 nm, G4coG3R) and 585-775 nm (λex = 
470 nm, A3D), using a sequential acquisition mode. The pinhole diameter was set at 1.0 Airy unit 
giving 0.89 µm optical slice thickness. 12 bit numerical images were obtained with Leica SP8 LAS 
X software (Version 3.1.5, Leica, Germany). 
 
2.7 In vitro anticancer activity 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay was used to 
evaluate the cytotoxicity of the different polymer prodrug nanoparticles. Briefly, cells (5 × 103 per 
well) were seeded in 96-well plates. After an overnight incubation, cells were then exposed to a series 
of increasing concentrations of polymer prodrugs, control polymers or free drugs for 72 h. Note that 
for heterobifunctional polymer prodrug nanoparticles and the co-nanoprecipitation formulation, the 
concentration refers to the concentration of each drug. 20 μL of MTT solution (5 mg.mL-1 in PBS) 
were then added in each well. Plates were incubated for 1 h at 37 °C followed by removal of the 
medium and addition of 200 μL of DMSO to each well to dissolve the formazan crystals. Absorbance 
was measured at 570 nm using a plate reader (Metertech Σ 960, Fisher Bioblock, Illkirch, France). 
The percentage of surviving cells was calculated as the absorbance ratio of treated to untreated cells. 
The inhibitory concentration 50% (IC50) of the treatments was determined from the dose-response 
curve. All experiments were repeated at least two times (6 replicates per condition) to determine 
means and SDs and the Student’s t-test was used to determine statistical differences. 
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3. Results and Discussion 
3.1 Design rationale 
Whereas the synthesis of α-functional polymers by RDRP from corresponding functional initiators 
is rather straightforward and usually leads to quantitative functionalization, their efficient ω chain-
end functionalization is much more challenging. Among the different end-functionalization routes for 
NMP-derived polymers [37], the nitroxide exchange reaction was selected. This method relies on a 
thermally-governed substitution of the nitroxide at the ω chain-end of a preformed polymer by a free 
nitroxide present in the medium. One of the most important advantages of this post-functionalization 
reaction relies on the absence of any other reactants than the polymer itself and the free nitroxide, 
which greatly simplifies the purification procedure [38-43]. Moreover, providing experimental 
conditions are optimized, a small excess of free nitroxide with respect to the polymer is generally 
enough for a quantitative functionalization. This is for instance the case when the newly formed 
polymer-nitroxide bond (termed macroalkoxyamine) is less labile than the original one (e.g., by 
exchanging SG1 by the TEMPO nitroxide [44, 45] or TEMPO by the TMIO nitroxide [43]), thus 
acting as an efficient driving force.  
 Combining the “drug-initiated” method and the nitroxide exchange with a nitroxide bearing 
a biologically active moiety thus appeared as an elegant route, to prepare a variety of different 
heterotelechelic polymers for drug delivery and imaging applications. Moreover, this strategy is 
rather unexplored for biomedical applications [41], and has never been applied to polymer prodrugs. 
This general drug delivery platform was built by polymerizing isoprene from a drug-bearing 
alkoxyamine based on the nitroxide SG1 [13-16], followed by the nitroxide exchange to position a 
functional TEMPO nitroxide bearing the molecule of interest at the ω chain end. Polyisoprene (PI) 
was chosen for its degradability [46-49] and biocompatibility [50], resulting from its structural 
similarity with natural terpenoids such as retinol, vitamin E or squalene, which are all biocompatible 
compounds. Interestingly, the interest of PI as drug nanocarriers has already been demonstrated both 
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in vitro and in vivo [13-15]. Also, substitution of SG1 by TEMPO through the nitroxide exchange 
reaction is known to be efficient [44] and should therefore lead to high chain-end functionalization 
from functional TEMPO derivatives. 
To provide the proof of concept, we illustrated our construction approach by the synthesis of 
two different model combinations: (i) gemcitabine/rhodamine (Gem/Rho) for drug delivery and 
imaging and (ii) aminoglutethimide/doxorubicin (Agm/Dox) for combination therapy. Gem was 
selected as an anticancer drug for its activity against a wide range of solid tumors (e.g., colon, lung, 
pancreatic, breast, bladder and ovarian cancers) [51] and Rho as an imaging probe because it offers a 
combination of advantageous properties such as a good photostability, a high extinction coefficient, 
a high quantum yield and an emission wavelength higher than those commonly associated with 
autofluorescence of cells in vitro [52]. Also, the Rho moiety derived from a tertiary amide to avoid 
intramolecular cyclization (which would result in a loss of fluorescence) and thus withholding of the 
fluorescence emission under a broad range of pH [32].  
As for the combination therapy, Dox and Agm where selected as anticancer drugs [53-56] 
because their association was already investigated by grafting them to the backbone of poly(N-(2-
hydroxypropyl)methacrylamide) (PHPMA), resulting in an enhanced cytotoxicity in vitro [55, 56]. 
Dox is a leading drug in anticancer therapy, with a proved efficacy against a broad spectrum of solid 
tumor such as ovary, breast, thyroid, lung and soft tissue sarcomas [57]. Agm is an aromatase inhibitor 
[58], used as a second line therapy in advanced breast cancer [59].  
 
3.2 Feasibility of the nitroxide exchange reaction  
Given the nitroxide exchange reaction has never been performed on PI, we first investigated the 
feasibility of this reaction by electronic spin resonance (ESR) on a model PI-SG1 (P1, synthesized 
by NMP from the AMA-SG1 alkoxyamine) and free TEMPO to find the best reaction conditions. To 
do so, the activation energy of PI-TEMPO and PI-SG1 macroalkoxyamines were first determined. It 
has indeed been shown that the required amount of nitroxide used for the exchange reaction is related 
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to the bond dissociation energy of the precursor and the exchanged (macro)alkoxyamines [43, 44]. 
Whereas numerous (macro)alkoxyamines based on TEMPO and SG1 have been prepared and their 
dissociation analyzed by ESR, there is no data for PI-based macroalkoxyamines or model alkyl 
moieties. The dissociation of PI-SG1 (P1) was first monitored at 385.5 K. A kd value of 8.43 10-4 s-1 
was obtained leading to an activation energy Ea = 128.8 kJ.mol-1 (Figure S1a). This value is relatively 
close to the PS-SG1 macroalkoxyamine (Ea = 125 kJ.mol-1), which is also an alkoxyamine bearing a 
secondary alkyl moiety with a relatively low polarity [60]. The dissociation rate constant of a PI end-
capped by a TEMPO derivative (G2R) was also determined. At 413 K, kd = 6.12 10-4 s-1, which 
corresponds to an activation energy Ea = 139 kJ.mol-1; that is a 10 kJ.mol-1 difference with P1 (Figure 
S1b). Such a difference is in good agreement with SG1- and TEMPO-based alkoxyamines bearing 
other alkyl moieties (8.5 and 11.1 kJ.mol-1 difference for the styryl and benzyl moiety, respectively) 
[37] and similar to the one between PS-SG1 and PS-TEMPO [44].  
ESR is also a method of choice to determine the living fraction (LF) of macroalkoxyamines; 
that is the amount of polymer end-capped by the nitroxide. It was shown that the LF of a nitroxide-
terminated polymer is strongly dependent on the polymerization conditions and the molar mass of the 
polymer [61]. The LF of three Gem-PI-SG1 samples of different molar masses (G1, G5 and G6) were 
measured by ESR (Table 1). As expected the LF values were very high (81-98 mol.%) with a nearly 
quantitative livingness for the lowest Mn, indicating that Gem-PI-SG1 is suitable for the nitroxide 
exchange from TEMPO derivatives. 
Therefore, these preliminary studies on model PI-based macroalkoxyamines successfully 
established the feasibility of this approach. 
 
3.3 Heterotelechelic polymer prodrug synthesis 
For both heterotelechelic polymer prodrugs (i.e., Gem-PI-Rho and Agm-PI-Dox), the drug in α 
position (i.e., Gem or Agm) was covalently linked to the AMA-SG1 alkoxyamine, followed by NMP 
of isoprene to yield the corresponding α-functional PI-SG1 prodrugs (Scheme 1 and Scheme 2). They 
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were then subjected to the nitroxide exchange reaction from a functional TEMPO nitroxide bearing 
either Rho or Dox, to yield the desired heterotelechelic polymer prodrugs. 
 
3.3.1 Synthesis of heterotelechelic polymer prodrugs for drug delivery and imaging (Gem-PI-Rho) 
 
 
Scheme 1. (a) Synthesis of TEMPO-Rho and (b) heterobifunctional Gem-PI-Rho polymer prodrug 
by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Gem-AMA-SG1 
alkoxyamine followed by nitroxide exchange from TEMPO-Rho. PI = polyisoprene, Gem = 
gemcitabine and Rho = rhodamine. 
 
The synthetic route to prepare Gem-PI-Rho prodrugs is presented in Scheme 1. By adjusting the 
polymerization time or the monomer/initiator molar ratio [13], a small library of Gem-PI (G1-G6) of 
different molar masses was synthesized by NMP of isoprene from the Gem-bearing alkoxyamine 
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AMA-SG1 (Scheme 1b and Table 1). The resulting polymers exhibited low dispersity (Đ = 1.20-
1.59) and high drug loadings up to 38 wt.%, which is ~10 times higher than most traditional drug-
loaded nanoparticles.  
 
Table 1. Characterization of Gem-PI and Gem-PI-Rho Polymer Prodrugs (G = Gem-PI, GR = 
Gem-PI-Rho). 
Prodrug Mn,SECa 
(g.mol-1) 
Ða 
 
Mn,NMR 
(g.mol-1) 
DPn,NMRd Rho/Geme Drug loading 
(wt.%) f 
Living fraction 
(LF, mol.%)g 
G1 700 1.59 1360b 11 - 37.6 98 
G2 1320 1.55 2230b 24 - 19.9 - 
G3 2410 1.30 4170b 52 - 10.9  - 
G4 2880 1.20 2450b 27 - 9.1  - 
G5 4750 1.30 4580b 58 - 5.5  81 
G6 7340 1.20 4180b 52 - 3.6 83 
G2R 2040 1.26 3000c 28 0.95 12.9 - 
G3R 2530 1.30 4280c 46 0.97 10.4 - 
a Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada parameters.  
b Calculated according to Mn,NMR = (DPn,NMR x MWisoprene) + MWalkoxyamine. c Calculated according to Mn,NMR = (DPn,NMR x 
MWisoprene) + MWAMA-Gem+ MWTEMPO-Rho.  d Calculated from ratio of areas under the peak at 6.1-6.3, 7.3-7.5, 8.0-8.2 ppm 
(aromatic and anomeric proton of Gem) and 5.0-5.5 ppm (vinylic H in isoprene repeat unit (1,4-addition), corresponding 
to ~81% of total isoprene units). e Calculated from ratio of areas under the peak of aromatic protons of Rho at 7.8-7.6, 
7.6-7.5, 7.1-7.0, 6.9-6.8 ppm and aromatic and anomeric protons of Gem at 6.1-6.3, 7.3-7.5, 8.0-8.2 ppm.  f Calculated 
according to MWGem/Mn,SEC. g Determined by ESR.  
 
To confer imaging ability to Gem-PI prodrugs by nitroxide exchange, a TEMPO nitroxide 
functionalized by a Rho moiety was synthesized (Scheme 1a). Hydroxy-TEMPO was reacted with 
succinic anhydride, while rhodamine B was functionalized with a piperazine ring. TEMPO-Rho was 
then obtained with a 68% overall yield via amidation using HATU as coupling agent. The nitroxide 
exchange reaction was then performed in pyridine at 110° C for 16 h. SEC analysis (DRI detector) of 
the starting Gem-PI-SG1 (G2 and G3) and the resulting Gem-PI-Rho (G2R and G3R) did not show 
any noticeable occurrence of chain termination reaction by recombination (Figure S2a and S2b). Also, 
SEC via fluorescence detection confirmed that Gem-PI-SG1 chains have been homogeneously end-
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capped by TEMPO-Rho moieties as both RI and fluorescence traces of Gem-PI-Rho G2R and G3R 
showed the same molar mass distribution profile (Figure S3). 
 
 
Figure 2. (a) Monitoring of the nitroxide exchange reaction between Gem-PI-SG1 (G6) and TEMPO-
Rho (three-line signal refers to TEMPO and six-line signal refers to SG1). (b) Conversion of Gem-
PI-SG1 (G6) into Gem-PI-TEMPO-Rho. 
 
The presence of TEMPO-Rho at the polymer ω chain-end was first quantitatively measured by 1H 
NMR (Figure S4). The NMR spectrum of Gem-PI-Rho (G3R) showed the aromatic peaks of Gem 
and the appearance of protons from Rho in the 4-4.5 ppm region corresponding to the piperazine ring 
and to protons in α position to the amine, and in the 8-6.5 ppm region corresponding to the aromatic 
protons of Rho. By comparing the aromatic and anomeric peaks of Gem with the aromatic peaks of 
Rho, post-functionalization yields for G2R and G3R, were 95 and 97 mol.%, respectively. Moreover, 
the complete disappearance of the proton signal in the 3.2-3.4 ppm region (proton in α position to the 
phosphorous atom of SG1) further supported the quantitative chain-end functionalization. 
 To confirm NMR data, ESR was used to monitor the kinetics of the nitroxide exchange 
reaction between Gem-PI-SG1 (G6) and TEMPO-Rho directly inside the ESR cavity. Because of the 
high sensibility of the ESR apparatus, the concentration of both reactants was lowered down to 1.0 x 
10-3 M, while maintaining an equimolar G6:TEMPO-Rho ratio. Since the decomposition is a first 
order kinetics and the trapping of the macroradical is very fast, influence of the concentration is 
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assumed to be very weak. Note that the exchange reaction has been performed in pyridine for 
solubility reasons, which is known to increase the rate of dissociation because of its high polarity via 
stabilization of both the polar transition state and the released nitroxide. According to the literature, 
the activation energy for the dissociation in polar solvent usually decreases by ~1-3 kJ.mol-1, with a 
faster decomposition for polar SG1-based compounds than for TEMPO-based counterparts [62]. 
At the beginning of the reaction, a three-line signal corresponding to the TEMPO nitroxide 
was overlaid with a small amount of residual SG1 nitroxide, according to the presence of a 
characteristic six-line signal (Figure 2a). Upon heating, the intensity of the SG1 nitroxide increased 
but rapidly decreased because of degradation reactions (Figure 2a and S5). It has been already shown 
that in some solvents (e.g., DMF), the SG1 nitroxide is not stable at high temperature [63]. Therefore, 
the low stability of the SG1 nitroxide in such conditions avoided the direct monitoring of the exchange 
reaction since the total amount of the free nitroxide was not stable.  
Nevertheless, by subtracting the signal of the SG1 nitroxide to the total amount of free 
nitroxide in the medium, it was possible to determine the evolution with time of the concentration of 
TEMPO-Rho nitroxide in solution (Figure S5) and thus the amount of TEMPO-Rho coupled to Gem-
PI macroradicals (Figure 2b). An exponential increase of the desired heterotelechelic Gem-PI-Rho 
followed by a plateauing of the conversion close to 80% were obtained. Such a value is in line with 
the LF value determined earlier for Gem-PI-SG1 (G6, LF = 83%), showing that the exchange reaction 
was quantitative under these conditions (i.e., each SG1 nitroxide was replaced by a TEMPO-Rho). It 
is also worth mentioning that, similarly to the exchange between TMIO and TEMPO nitroxides [43], 
a 1:1 molar ratio between the SG1-terminated polymer and the functional TEMPO was enough to 
reach a nearly quantitative functionalization, which represents an important advantage over other 
procedures [44]. 
ESR was also used to assess the purity of Gem-PI-Rho polymers. They were heated up at 140 
°C for 2 h to perform a quantitative release of the nitroxide, whether it is SG1 or TEMPO. Not only 
ESR analyses did not show any remaining trace of free functional TEMPO before heating, but only 
21 
 
TEMPO-related signals were obtained after heating, as a result of a very efficient purification process 
and a quantitative nitroxide exchange reaction since no SG1 signal was observed (Figure S6). 
 
3.3.2 Synthesis of heterotelechelic polymer prodrugs for combination therapy (Agm-PI-Dox) 
Agm-PI-Dox polymer prodrugs were synthesized following the same synthetic route (Scheme 2). 
 
 
Scheme 2. (a) Synthesis of TEMPO-Dox and (b) heterobifunctional Agm-PI-Dox polymer prodrug 
by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Agm-AMA-SG1 
alkoxyamine followed by nitroxide exchange from TEMPO-Dox. Agm = aminoglutethimide, PI = 
polyisoprene and Dox = doxorubicin. 
 
Agm-AMA-SG1 was prepared via PyBoP coupling between AMA-SG1 and Agm with a 69 % yield 
(Scheme 2b and Figure S7) and subsequently used to initiate the NMP of isoprene in 1,4-dioxane at 
115 °C. A small library of Agm-PI (A1-A3) was synthesized and reacted with TEMPO-Dox 
(previously prepared by coupling hydroxy-TEMPO and Dox by HATU-assisted coupling, see 
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Scheme 2a), to give the corresponding Agm-PI-Dox (A1D-A3D, Table 2). These heterobifunctional 
polymer prodrugs bearing both drugs exhibited variable molar masses and low dispersities (Mn,SEC = 
3370-6500 g.mol-1, Đ = 1.22-1.39). As with Rho, Dox fluorescence enabled to evaluate the 
effectiveness of the nitroxide exchange reaction and the purity of the final polymer by SEC (Figure 
S8). The efficiency of the exchange reaction was calculated by 1H NMR by comparing the aromatic 
proton signals of Dox and Agm (Table 2). It was quantitative for A1D (Figures S9-S10) and as high 
as ~95% for A2D. Here again, the complete disappearance of the proton signal in α position to the 
SG1 phosphorous atom was observed. However, it was not possible to obtain a reliable measurement 
of the exchange efficacy by ESR likely because Dox acted as a radical scavenger via its quinone ring. 
The successful coupling of Dox was also proved by UV spectroscopy based on a calibration curve 
using free Dox. The amount of Dox coupled to the polymers for A1D-A3D ranged from 79% to 
quantitative. The nitroxide exchange reaction was also applied to PI (P1) from TEMPO-Dox using 
optimized experimental conditions reported earlier and yielded PI-Dox (D1) as a control 
monofunctional polymer prodrug (Figure S11). 
 
Table 2. Characterization Of Agm-PI, PI-Dox And Agm-PI-Dox Polymer Prodrugs (A = Agm-PI, 
AD = Agm-PI-Dox, D = PI-Dox). 
Prodrug Mn,SEC a 
(g.mol-1) 
Ða 
 
Mn,NMR 
(g.mol-1) 
DPn,NMRd Dox/Agme Total drug loadingf 
(wt.%) 
Doxi 
(mol.%) 
A1 2780 1.22 2610b 30 - 8.0f - 
A2 3850 1.33 3520b 43 - 5.8f - 
A3 5100 1.39 7290b 99 - 4.4f - 
A1D 3370 1.18 3340c 33 quant. 23.0g quant. 
A2D 4620 1.27 4520c 50 95 16.8g quant. 
A3D 6500 1.28 7070c 88 82 11.9g 79.2 
D1 3210 1.22 - - - 16.9 h 65.0 
a Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada parameters.  
b Calculated according to Mn,NMR = (DPn,NMR x MWisoprene) + MWalkoxyamine. c Calculated according to Mn,NMR = (DPn,NMR x 
MWisoprene) + MWAMA-Agm + MWTEMPO-Dox. d Calculated from ratio of areas under the peak at 7.20-7.25, 7.50-7.58 ppm 
(aromatic proton of Agm) and 5.0–5.5 ppm (vinylic H in isoprene repeat unit (1,4-addition), corresponding to ~81% of 
total isoprene units). e Calculated from ratio of areas under the peak of the aromatic protons of Dox at 8.2-8.1, 7.9-7.7, 
7.4-7.3 and aromatic protons of Agm at 7.6-7.5, 7.2-7.1.  f Calculated according to MWAgm/Mn,SEC. g Calculated according 
to (MWAgm + MWDox)/Mn,SEC. h Calculated according to MWDox/Mn,SEC. i Determined by UV spectroscopy. 
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All these data indicated a (nearly) quantitative ω-functionalization of “drug-initiated” SG1-
terminated PI by the nitroxide exchange reaction from TEMPO nitroxides, bearing either a 
fluorescent probe or another drug, to yield the corresponding well-defined heterotelechelic polymer 
prodrugs. The general synthetic scheme proved to be simple, yet efficient, with good yields and most 
importantly very flexible since both chain-ends were readily functionalized with the desired molecule. 
By combining the quantitative α-functionalization of the drug-initiated” method and the nearly 
quantitative nitroxide exchange reaction, ~1:1 molar ratios between both chain-end moieties were 
obtained. Note that the nitroxide exchange reaction was conducted to completion to test the robustness 
of the strategy but it could easily be tuned to target any kind of intermediate ratios simply by playing 
with the amount of functional TEMPO in the medium during the exchange reaction. 
 
3.2 Nanoparticles formulation and colloidal characteristics 
Fluorescent polymer nanoparticles are usually obtained by hydrophobic dye encapsulation during the 
nanoparticle formulation process. However, strong limitations are often observed including potential 
leakage of the fluorescent dye out from the nanoparticles, resulting in inaccurate or even wrong 
interpretations of fluorescence images [64]. Covalent linkage of the fluorescent dye to the polymer 
nanoparticle is therefore highly desirable. A convenient strategy to fluorescently label “drug-
initiated” polymer prodrug nanoparticles is to grow a short PI chain from a fluorescent dye and to co-
nanoprecipitate a small amount of the resulting dye-polymer with a drug-polymer prodrug obtained 
by the “drug-initiated” method, leading to mixed nanoparticles containing both the dye and the drug 
separately linked to a PI chain. This approach has been illustrated by the co-nanoprecipitation of a 
few wt.% of naphthalimide-PI (Napth-PI) with CdA-PI, leading to mixed nanoparticles suitable for 
imaging studies by confocal microscopy while still maintaining their cytotoxic activity to cancer cells 
[16]. However, such a blending strategy always resulted in decrease of the overall drug loading 
compared to nanoparticles only made from monofunctional drug-polymer conjugates. This issue can 
be easily overcome by blending heterotelechelic polymer prodrugs comprising both the drug and the 
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imaging agent with the drug-polymer to keep a nearly constant drug loading. We illustrated this 
strategy by the co-nanoprecipitation of Gem-PI (G4) with 5 wt.% Gem-PI-Rho (G3R), giving 
fluorescent nanoparticles of 161 nm in average diameter with narrow particle size distribution and 
the same drug loading as pure Gem-PI nanoparticles G4 (Table 3). The surface charge of G4coG3R 
nanoparticles increased compared to that of G4 nanoparticles, as the result of the surface positioning 
of positively charged Rho moieties. 
 
Table 3. Characterization Of Gem-PI-Rho Nanoparticles (G = Gem, GR = Gem-PI-Rho). 
Prodrug 
Dza 
(nm) 
PSDa 
ζa 
(mV) 
%Gemb 
(wt. %) 
G4 68 0.134 -29.1 9.1 
G4coG3R 161 0.077 12.5 9.3 
a Measured by dynamic light scattering (DLS) as an average of three different measures. b Calculated according to 
MWGem/(Mn,SEC(G4)*95/100 + Mn,SEC(G3R)*5/100). 
 
Heterobifunctional polymer prodrug nanoparticles for combination therapy were obtained by 
nanoprecipitation of Agm-PI-Dox (A1D-A3D) at a concentration of 2.5 mg mL-1 in water without 
any surfactant (Table 4). The co-nanoprecipitation of A3 and D1 (1:1 mol ratio), leading to Agm-
PIcoPI-Dox (A3coD1), together with the nanoprecipitation of the corresponding monofunctional 
polymers Agm-PI (A3) and PI-Dox (D1), were also performed. The different heterotelechelic 
polymer prodrug nanoparticle suspensions exhibited average diameters ranging from 63 to 122 nm 
as measured by DLS, narrow particle size distributions and strongly negative surface charges, that is 
forerunner of a high colloidal stability (Table 4). Cryo-TEM images of Agm-PI-Dox nanoparticles 
showed spherical morphologies with average diameters in agreement with DLS data (Figure 3c).  
Importantly, drug loadings of heterotelechelic polymer prodrug nanoparticles (A1D-A3D) 
were significantly higher compared to their counterpart obtained by co-nanoprecipitation (A3coD1) 
where more polymer was required for the co-nanoprecipitation to keep the same drug ratio, which is 
an important advantage provided by those materials. 
25 
 
Table 4. Characterization Of Agm-PI, Agm-PI-Dox And PI-Dox Prodrug Nanoparticles (A = Agm, 
AD = Agm-PI-Dox, D = Dox). 
Prodrug Dz
a 
(nm) PSD
a ζ
a 
(mV) 
Agmb 
(wt.%) 
Doxc 
(wt.%) 
A3 151 0.033 -23 4.4 - 
A1D 122 0.096 -43 6.9 16.1 
A2D 76 0.126 -39 5.0 11.8 
A3D 63 0.100 -31 3.5 8.4 
D1 66 0.211 -29 - 16.9 
A3coD1 161 0.154 -69 2.8 6.5 
a Measured by dynamic light scattering (DLS) as an average of three different measures. b Calculated according to 
MWAgm/Mn,SEC. c Calculated according to MWDox/Mn,SEC. 
 
The long term colloidal stability of the different nanoparticles was also assessed over a period of 30 
days in water as both the average diameters and the PSD values were constant (Figure 3a and Figure 
S12a). 
 
 
Figure 3. Evolution of the average diameters (Dz) and the particle size distributions (PSD) measured 
by DLS of Agm-PI-Dox nanoparticles (A1D, A2D, A3D) in (a) water and (b) cell culture medium 
(A2D, A3D). (c) Representative Cryo-TEM image of Agm-PI-Dox nanoparticles A3D (scale bar = 
100 nm). 
 
For Agm-PI-Dox nanoparticles, the higher the Mn, the lower the average diameter and the PSD, in 
good agreement with literature data on PI-based prodrugs [14]. Interestingly, polymer prodrugs based 
on Dox led to smaller nanoparticles, which could be explained by π-π interaction between Dox 
molecules, resulting in denser and thus smaller nanoparticles [65]. These results are in line with UV-
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Vis spectroscopy measurements, which showed a redshift of the nanoparticle absorbance of about 25 
nm, assigned to stacking interactions (Figure S13).[66, 67] Importantly, Agm-PI-Dox nanoparticles 
(A1D-A3D), Agm-PIcoPI-Dox nanoparticles (A3coD1) and their monofunctional counterparts also 
exhibited great colloidal stability in cell culture medium up to two weeks (Figure 3b and Figure S12b).  
 
3.3 Imaging studies 
Confocal microscopy was used to monitor the cellular uptake of Gem-PI/Gem-PI-Rho (G4coG3R) 
nanoparticles by MCF7 breast cancer cells to assess their subcellular localization. The cells were 
incubated with G4coG3R nanoparticles (red channel) for 90 min and successively with LysoTracker 
Green (green channel) and Hoechst 33342 (blue channel), for selective staining of the lysosomes and 
the nucleus, respectively. Gem-PI-Rho nanoparticles proved to be suitable for cell imaging as a strong 
red fluorescence signal was observed even with a relatively low amount of Rho (i.e., 5 wt.% of G3R). 
By overlaying the red, green and blue channels, yellow colocalization spots were observed indicating 
that Gem-PI-Rho nanoparticles were accumulating into the lysosomes (Figure 4a-f), which was 
further supported by analysis of the fluorescence intensity profiles (Figure 4g and 4h). 
 
27 
 
 
Figure 4. (a) Nomarski image of MCF7 cells, (b-d) confocal microscopy images [(b) green 
(LysoTracker Green), (c) blue (Hoechst 33342) and (d) red (Gem-PI/Gem-PI-Rho G4coG3R) 
channels], (e) merge of green, blue and red fluorescence images, (f) merge of green, blue and red 
channels with Nomarski image (arrows indicate colocalization), (g) confocal microcopy image 
(merge of green, blue and red channels) and (h) associated fluorescence intensity profiles. Scale bars 
= 20 µm.  
 
By taking advantage of the inherent fluorescence of Dox, a similar cell imaging experiment was 
performed with Agm-PI-Dox (A3D) nanoparticles. MCF7 cells were subjected to the same treatment 
as for G4coG3R nanoparticles and CLSM images also revealed a bright, red fluorescence signal 
inside the cells. By overlaying the red, green and blue channels, yellow colocalization spots were 
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observed, suggesting that A3D nanoparticles were in the lysosomes (Figure 5), conversely to free 
Dox that was already found in the nucleus after the same time period (Figure S14). This observation 
is in agreement with the polymer prodrug concept, whereby the drug needs to get cleaved from the 
polymer before being pharmacologically active. It therefore resulted in a delayed internalization of 
Dox in the nucleus from Agm-PI-Dox (A3D) nanoparticles conversely to free Dox. 
 
 
Figure 5. (a) Nomarski image of MCF7 cells, (b-d) confocal microscopy images [(b) green 
(LysoTracker Green), (c) blue (Hoechst 33342) and (d) red (Agm-PI-Dox A3D) channels], (e) merge 
of green, blue and red fluorescence images, (f) merge of green, blue and red channels with Nomarski 
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image (arrows indicate colocalization), (g) confocal microcopy image (merge of green, blue and red 
channels) and (h) associated fluorescence intensity profiles. Scale bars = 20 µm. 
 
Overall, both Gem-PI-Rho and Agm-PI-Dox prodrug nanoparticles proved to be suitable for cellular 
imaging, with fluorescence signals originating from a dedicated fluorescent probe attached to the 
polymer chain-end or directly from a fluorescent drug. 
 
3.4 In vitro cytotoxicity 
A cytotoxicity study was first performed with Gem-PI/Gem-PI-Rho nanoparticles (G4coG3R) on the 
human breast cancer cell line MCF7. The cells were incubated for 72 h with increasing concentrations 
of G4, G4coG3R or free Gem to determine IC50 values. G4coG3R nanoparticles showed a similar 
cytotoxicity profile than that of pure Gem-PI nanoparticles (G4), with IC50 = 65 µM (Figures 6a and 
S15), showing that fluorescent labeling by chain-end functionalization did not interfere with the 
cytotoxicity profile. As expected, free Gem exhibited a lower IC50 value of 6 nM because of the 
prodrug nature of G4 and G3R.  
The in vitro cytotoxicity of Agm-PI-Dox nanoparticles and their monofunctional counterparts 
was then investigated on MCF7 cells under identical experimental conditions. The IC50 values were 
compared to those of the free drugs (alone or in association). Whereas neither PI nanoparticles (P1) 
nor free Agm were cytotoxic at these concentrations (no IC50 values could be measured), as 
previously observed [13-15, 55, 56, 68] (Figure S16), free Dox led to an IC50 value of 0.29 µM, 
similarly to the 1:1 (mol:mol) physical mixture of free Dox and Agm (Figures 6b and S17). Coupling 
Agm to PI resulted in a drastic increase of the cytotoxicity as PI-Agm prodrug nanoparticles (A3) 
gave an IC50 of 3.16 µM, which could be explained by an efficient internalization of the nanoparticles 
and/or protection from early metabolism [69, 70]. Conversely, PI-Dox (D1) nanoparticles showed a 
reduced cytotoxicity compared to free Dox with an IC50 of 5.1 µM, as commonly seen for prodrugs 
because the drug must be released from the promoiety before recovering its activity.  
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Figure 6. (a) IC50 values ± SD of Gem-PI (G4), Gem-PI (G4)/Gem-PI-Rho (G3R, 5 wt.%) and free 
Gem on MCF7 cells after incubation of 72 h. (b) IC50 values ± SD of Agm-PI-Dox (A1D-A3D), 
Agm-PI (A3), PI-Dox (D1), Agm-PIcoPI-Dox (A3coD1) nanoparticles and free drugs determined by 
MTT test on MCF7 cells after 72 h of incubation (** p < 0.01 vs. D1, * p < 0.05 vs. A3). 
 
Very importantly, heterobifunctional Agm-PI-Dox nanoparticle (A1D-A3D) showed lower IC50 
values than monofunctional Agm-PI or PI-Dox nanoparticles, which induced the highest cytotoxicity 
deriving from the dual functionalization (Figures 6b and S17). Moreover, they were also more active 
than the co-nanoprecipitation of both monofunctional polymers at the same molar ratio (A3coD1). 
These results are in good agreement with literature data showing that having both drugs linked to the 
same polymeric backbone resulted in enhanced cytotoxicity [55, 56]. 
Also, the higher the Mn of PI for Agm-PI-Dox nanoparticle (A1D-A3D), the higher the 
cytotoxicity, as already observed for monofunctional “drug-initiated” polymer prodrug nanoparticles 
[19]. This trend may be assigned to an enhanced internalization into cancer cells related to the surface 
hydrophobicity of the nanoparticles and/or their colloidal properties (a lower average diameter is 
observed when the Mn is increased). Agm-PI-Dox nanoparticle A1D with the lowest Mn gave an IC50 
of 2.82 µM, close to Agm-PI (A3), while IC50 values of higher Mn Agm-PI-Dox nanoparticle A2D 
and A3D were in the 1.8-1.9 µM range. It represents a ~50% decrease in IC50 compared to Agm-PI 
nanoparticles (A3) and ~65% compared to PI-Dox nanoparticles (D1). Interestingly, the same 
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beneficial effect is not present when Dox and Agm are combined as free drugs, leading a similar IC50 
value than that of free Dox (0.28 vs. 0.29 µM, respectively). The Combination Index (CI), which is 
recognized as the standard measure of combination effect [71], indicated an additive effect for A3D 
(CI = 0.98) and a slightly synergistic effect for A2D (CI = 0.91), whereas A3coD1 led to a lesser 
effect than the expected additive effect (CI = 2.1). 
 
4. Conclusion 
By combining the “drug-initiated” method and the nitroxide exchange reaction from functional 
nitroxides, we developed a general approach to design heterotelechelic polymer prodrug 
nanoparticles, with drug loading up to 23 wt.%, for application in drug delivery, imaging and 
combination therapy. This novel approach is: (i) simple as it only requires a few synthetic steps and 
only the α-functional polymer and the functional nitroxide are required (i.e., no catalyst or other 
reagents) which simplifies the purification procedure and leads to high yields; (ii) efficient and robust 
as (nearly) quantitative chain-end functionalizations are obtained and (iii) versatile as it is applicable 
to a broad range of different biologically active molecules (e.g., drug, dyes). 
In the context of this study, the proof of concept was validated by the synthesis of two different 
combinations: one with Gem and Rho for drug delivery and imaging, and one with Agm and Dox for 
combination therapy. Whereas Gem and Rho induced significant cytotoxicity to cancer cells and 
efficient fluorescent labeling, respectively, combining Agm and Dox led to enhanced cytotoxicity 
compared to monofunctional polymer prodrug nanoparticle counterparts or their co-
nanoprecipitation. Note that the goal of this study was not to find the best drug ratio and/or 
combination for optimized cytotoxicity, but rather to prove the versatility of this approach by the 
coupling of three different anticancer drugs and one fluorescent dye.  
Another advantage of this approach would be the possibility to fine-tune the ratio between the 
two molecules of interest simply by adjusting the stoichiometry of the reactants. This is especially of 
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great interest in the context of combination therapy where any ratio between the two drugs can be 
obtained. 
Overall, the facile development of heterotelechelic polymer prodrug nanoparticles could 
provide the community with new synthetic and therapeutic opportunities as numerous drug 
combination for combination therapy can be explored. 
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